Kann sich jetzt jeder selbst ein Bild davon machen. Ich fasse mal die Rahmendaten kurz zusammen:
Die Produkte von Atossa sind super. Die große Frage, die sich hier stellt ist - ob sie mit Ihren Finanzen die Zeit überdauern können,
bis die klinischen Studien alle durch sind, und die Produkte dann VIELLEICHT eine Zulassung bekommen. Hab neulich gelesen, dass
nur ca. 15 % aller Produkte, die die klinische Studie Phase 1 bestehen und endgültig eine Zulassung bekommen.
Die Produkte, die Phase 3 bestehen bekommen zu 65% eine Zulassung und die Produkte, die Phase 4 bestehen zu 95% eine Zulassung.
Da dieser Prozess von Phase 1 bis Phase 4 zwischen 12 Monaten und ein paar Jahren gehen kann, ist die Frage, ob Atossa bis dahin
das Geld nicht ausgeht. Und falls ja, was ist dann der nächste logische Schritt? Natürlich... eine KE! Und wieviel KE´s werden dann kommen?
Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update
SEATTLE, March 26, 2020 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the fourth quarter and year ended December 31, 2019 and provides an update on recent company developments.
We are very proud of our 2019 accomplishments, as we focused on developing our proprietary drug Endoxifen to reduce mammographic breast density (MBD) and to treat breast cancer in the window of opportunity after a patient is diagnosed but before her surgery, said Dr. Steven Quay, Atossas President and Chief Executive Officer. We have received positive data from the expanded access (or, compassionate-use) patient taking our oral Endoxifen and from our Phase 2 study of our topical Endoxifen to reduce MBD, all while minimizing costs and managing our cash position.
Key strategic highlights for 2019 included:
Completed additional Phase 1 work with our proprietary oral Endoxifen.
Contracted with South General Hospital in Stockholm, Sweden to conduct a Phase 2 study with oral Endoxifen to reduce MBD.
Continued Phase 2 study underway in Australia administering our oral Endoxifen to newly diagnosed breast cancer patients in the window of opportunity.
In developing topical Endoxifen, Phase 2 studies showed significant and rapid reduction of MBD.
Received favorable results from our single-patient expanded access program: the Ki-67 activity decreased by 50%, and the estrogen receptor content decreased by more than 20% with no safety or tolerability issues, including vasomotor symptoms such as hot flashes and night sweats.
Received IRB approval for a Phase 2 clinical study using our intraductal microcatheter technology to administer fulvestrant in patients with early-stage breast cancer or ductal carcinoma in situ (DCIS) at a major institution.
RECENT CORPORATE DEVELOPMENTS
Recent developments include the following:
Changed the name of the company from Atossa Genetics to Atossa Therapeutics, which we believe more clearly reflects our focus on developing therapies and continues to honor Princess Atossa, the great queen of the Achaemenid Empire who reigned in the fifth century BCE and who is the earliest recorded woman with breast cancer.
Submitted an application to initiate a Phase 2 study of our oral Endoxifen for the reduction of MBD to the Swedish Medical Product Agency and the Institutional Review Board.
Announced that we will meet with the U.S. F.D.A. on April 30, 2020. The objective of this meeting is to discuss the clinical development of oral Endoxifen to reduce MBD.
2019 FINANCIAL RESULTS
For the years ended December 31, 2019 and 2018, we have no source of sustainable revenue and no associated cost of revenue.
Operating Expenses: Total operating expenses were $17.3 million for the year ended December 31, 2019, which is an increase of $5.8 million, or 51%, from the year ended December 31, 2018. Operating expenses for 2019 consisted of research and development (R&D) expenses of $6.6 million and general and administrative (G&A) expenses of $10.6 million. Operating expenses for 2018 consisted of R&D expenses of $4.2 million, and G&A expenses of $7.2 million.
Research and Development Expenses: R&D expenses for the year ended December 31, 2019, were $6.6 million, an increase of $2.4 million, or 58%, from total R&D expenses in 2018 of $4.2 million. The increase in R&D expense is attributed to non-cash stock-based compensation, salaries and clinical trial expenses associated with our Endoxifen program. R&D stock-based compensation expense, which is a non-cash charge, increased approximately $2.3 million during 2019 resulting from the cancellation of certain 2018 options and the 2019 replacement grant of options that were 75% vested and that were granted at fair market value on the date approval by the Board of Directors but were in-the-money on the date they were subsequently approved by the stockholders. There were no option cancellations or in-the-money option grants in the comparable period of 2018. Clinical trial expenses also increased by approximately $250,000 over the same period in 2018.
General and Administrative Expenses: G&A expenses were $10.6 million for the year ended December 31, 2019, an increase of $3.4 million, or 47% from the total G&A expenses for the year ended December 31, 2018, of $7.2 million. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses for the year ended December 31, 2019, is attributed to non-cash stock-based compensation. G&A stock-based compensation expense, which is a non-cash charge, increased approximately $4.0 million during 2019 resulting from the cancellation of certain 2018 options and the 2019 replacement grant of options that were 75% vested and that were granted at fair market value on the date of approval by the Board of Directors but were in-the-money on the date they were subsequently approved by the stockholders. There were no option cancellations or in-the-money option grants in the comparable period of 2018. The increase in 2019 expense G&A expense was offset by a reduction in bonus compensation expense of approximately $350,000 as a one-time 2018 bonus was not paid in 2019.
As of December 31, 2019, the Company had approximately $12.6 million in cash and cash equivalents and working capital of approximately $13.0 million.
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossatherapeutics.com.
FORWARD-LOOKING STATEMENTS
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossas products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossas drugs under development and other risks detailed from time to time in Atossas filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form10-K and 10-Q,each as amended and supplemented from time to time.
Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927
kyle.guse@atossainc.com
Investor Relations Contact:
Scott Gordon
Core IR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office:(516) 222-2560
scottg@corprominence.com
Source: Atossa Therapeutics, Inc.
ATOSSA THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
As of December 31, As of December 31,
Assets§ 2019 2018
Current assets
Cash and cash equivalents $ 12,581,136 $ 10,380,493
Restricted cash 110,000 110,000
Prepaid expenses 862,344 509,833
Research and development tax rebate receivable 739,656 518,098
Other current assets 26,130 30,942
Total current assets 14,319,266 11,549,366
Furniture and equipment, net 34,350 54,487
Intangible assets, net 68,542 99,375
Right-of-use asset 50,479
Other assets 17,218 17,218
Total Assets $ 14,489,855 $ 11,720,446
Liabilities and Stockholders Equity
Current liabilities
Accounts payable $ 293,171 $ 353,328
Accrued expenses 77,888 177,074
Payroll liabilities 899,420 935,070
Stock-based compensation liability 1,410,025
Lease liability 39,371
Other current liabilities 12,892 39,939
Total current liabilities 1,322,742 2,915,436
Long term liabilities
Lease liability long term 11,108
Total Liabilities 1,333,850 2,915,436
Commitments and contingencies
Stockholders equity
Preferred stock $0.001 par value; 10,000,000 shares authorized; 671 and 2,379 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively 1 2
Additional paid-in capital - Series B convertible preferred stock 670,999 2,378,997
Common stock $0.18 par value; 175,000,000 shares authorized, and 9,130,984 and 5,846,552 shares issued and outstanding, as of December 31, 2019 and December 31, 2018, respectively 1,643,565 1,052,372
Additional paid-in capital 104,912,480 82,204,902
Accumulated deficit (94,071,040 ) (76,831,263 )
Total Stockholders Equity 13,156,005 8,805,010
Total Liabilities and Stockholders Equity $ 14,489,855 $ 11,720,446
ATOSSA THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Year Ended December 31,
2019 2018
Operating expenses
Research and development $ 6,645,417 $ 4,209,981
General and administrative 10,620,008 7,224,252
Total operating expenses 17,265,425 11,434,233
Operating loss (17,265,425 ) (11,434,233 )
Other income 25,648 29,299
Loss before income taxes (17,239,777 ) (11,404,934 )
Income taxes
Net loss $ (17,239,777 ) $ (11,404,934 )
Deemed dividends attributable to preferred stock (11,479,308 )
Net loss applicable to common shareholders $ (17,239,777 ) $ (22,884,242 )
Loss per common share basic and diluted $ (2.03 ) $ (5.50 )
Weighted average shares outstanding basic and diluted 8,496,964 4,157,746
|
Thread abonnieren
